Pioglitazone and empagliflozin for fatty liver in type 2 diabetes
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have type 2 diabetes with an A1c between 7% and 10% (a blood sugar average over 3 months).
- You take metformin alone or with a sulfonylurea or a DPP-4 inhibitor (common diabetes pills).
- A liver scan within the last 3 months showed you have fatty liver (a score of 268 or higher on a FibroScan).
- You have at least one of: large waist size, high blood pressure (or taking medicine for it), high triglycerides (or taking medicine for them), low HDL cholesterol, high insulin resistance, or high C-reactive protein (a sign of inflammation).
- You have not changed your diabetes or metabolic medications in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
This study tests a new diabetes medicine called Enavogliflozin against an older drug, Pioglitazone, to see which works better for lowering blood sugar and improving heart health. If you have type 2 diabetes, take metformin plus another pill, and your A1C is between 7 and 10.5, this study may be an option for you.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial compares two medications, dapagliflozin and empagliflozin, to see which works better and is safer for people with type 2 diabetes and a high body mass index (BMI). If you are an adult with type 2 diabetes and a BMI of 23 or higher, this study might help find a treatment that also supports weight loss.
This study looks at how the liver uses energy (mitochondria) in people with type 2 diabetes and fatty liver disease. By understanding this, researchers may find better ways to treat liver problems.
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.